Compare JELD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | TNXP |
|---|---|---|
| Founded | 1960 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.5M | 231.3M |
| IPO Year | 2017 | N/A |
| Metric | JELD | TNXP |
|---|---|---|
| Price | $2.76 | $17.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 1 |
| Target Price | $4.23 | ★ $70.00 |
| AVG Volume (30 Days) | ★ 1.6M | 638.0K |
| Earning Date | 11-03-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,304,951,000.00 | $10,299,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $933.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $6.76 |
| 52 Week High | $10.09 | $72.00 |
| Indicator | JELD | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 43.38 |
| Support Level | $2.66 | $17.71 |
| Resistance Level | $3.00 | $19.35 |
| Average True Range (ATR) | 0.15 | 1.34 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 48.99 | 37.55 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.